Lokon's first clinical product, LOAd703, was granted Fast Track Designation in the U.S. by the FDA for the treatment of pancreatic cancer. LOAd703 is a gene engineering viral vector, a form of immunotherapy, which has shown promising results in early studies. Fast Track will support clinical development as meetings with the FDA can occur more frequently.
Lokon Pharma continues to develop TME gene engineering product for pancreatic cancer in combination with PD-1 antibody therapy.
Lokon Pharma and Baylor College of Medicine have published results from their joint trial testing an immunostimulatory gene therapy for patients with pancreatic cancer in the well renowned journal Lancet Oncology. The clinical data shows a 55% response rate and 91% disease control rate in the highest dose cohort which is higher than one would expect from standard chemotherapy treatment.
Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB to develop a novel therapeutic strategy to treat cancer.
“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already h
Uppsala, Sweden, August 28, 2020. Lokon Pharma AB, a leading biotechnology company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced an expansion of its current clinical collaboration with Roche to evaluate LOAd703, Lokon’s immunostimulatory armed gene therapy virus in combination with Tecentriq, Roche’s programm
An agreement between Lokon Pharma and Roche.....
Uppsala, Sweden, January 19, 2017 - The first patient has been treated with LOAd703 at Baylor College of Medicine in Houston, TX. LOAd703 is an immunostimulating oncolytic adenovirus developed by Lokon Pharma. The study is enrolling patients with pancreatic cancer who are not eligible for surgical resection. Patients will receive six intratumoral injections of LOAd703 in combination with standard
